Anti T-lymphocyte globulin - Neovii Biotech

Drug Profile

Anti T-lymphocyte globulin - Neovii Biotech

Alternative Names: Anti-T-lymphocyte immune globulin; Antithymocyte globulin - Fresenius; Antithymocyte immunoglobulin (rabbit) - Neovii Biotech; ATG S Fresenius; ATG-Fresenius-S; ENZN-2053; EZ-2053; Grafalon; US-ATG-F

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fresenius Biotech
  • Developer Neovii Biotech
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection; Transplant rejection
  • Discontinued Lung transplant rejection

Most Recent Events

  • 06 Dec 2016 Neovii Biotech completes a phase III trial for Graft-versus-host disease (Prevention) in USA and Australia
  • 03 Dec 2016 Adverse events and efficacy data from a phase III trial in Graft versus host disease presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 06 Oct 2016 Anti T-lymphocyte globulin (formerly antithymocyte globulin) licensed to Zydus-Cadila in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top